OKRAVISION

Replacing the Animal Source of Viscous Fluids Used in Cataract Surgery with the Okra Plant Source

Coordinatore	BOHUS BIOTECH AB    more  Organization address address: TRADGARDSGATAN 4 city: STROMSTAD postcode: 452 31 contact info Titolo: Mr. Nome: Daniel C. Cognome: Ogbonnaya Email: send email Telefono: +46 526 14686 Fax: +46 526 12622
Nazionalità Coordinatore	Sweden [SE]
Totale costo	1˙434˙467 €
EC contributo	1˙105˙000 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2012
Funding Scheme	BSG-SME
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-11-01   -   2014-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	BOHUS BIOTECH AB  Organization address address: TRADGARDSGATAN 4 city: STROMSTAD postcode: 452 31 contact info Titolo: Mr. Nome: Daniel C. Cognome: Ogbonnaya Email: send email Telefono: +46 526 14686 Fax: +46 526 12622	SE (STROMSTAD)	coordinator	416˙865.00
2	PRC ENGINEERING AB  Organization address address: REGNBAGSGATAN 8 B city: GOTEBORG postcode: 417 55 contact info Titolo: Mr. Nome: Mattias Cognome: Carlsson Email: send email Telefono: 4631652244 Fax: 4631231135	SE (GOTEBORG)	participant	281˙526.48
3	INDUSTRIAL CONTROL SOLUTIONS LIMITED  Organization address address: CARLTON ROAD ENTERPRISE HOUSE city: WORKSOP postcode: S81 7QF contact info Titolo: Mr. Nome: Steve Cognome: Mcdermott Email: send email Telefono: 441910000000 Fax: 441910000000	UK (WORKSOP)	participant	248˙690.12
4	SLATTUM PRODUKTER AS  Organization address address: TYRIV 5 city: HAGAN postcode: 1481 contact info Titolo: Mr. Nome: Pål Cognome: Fredriksen Email: send email Telefono: 4767077136	NO (HAGAN)	participant	136˙989.00
5	MDT MEDICAL DEVICE TESTING GMBH  Organization address address: GRENZENSTRASSE 13 city: OCHSENHAUSEN postcode: 88416 contact info Titolo: Dr. Nome: Dieter R. Cognome: Dannhorn Email: send email Telefono: 49735291140 Fax: 497353000000	DE (OCHSENHAUSEN)	participant	8˙723.00
6	OSAUHING EESTI INNOVATSIOONI INSTITUUT  Organization address address: SEPAPAJA 6 city: TALLINN postcode: 11415 contact info Titolo: Mr. Nome: Lauri Cognome: Nirgi Email: send email Telefono: +372 6101032 Fax: +372 6101038	EE (TALLINN)	participant	6˙989.04
7	NOVAMINA CENTAR INOVATIVNIH TEHNOLOGIJA DOO  Organization address address: JACKOVINSLI KLANEC 17 city: Zagreb postcode: 10000 contact info Titolo: Mrs. Nome: Jasmina Cognome: Petrinovic Email: send email Telefono: +385 1 3499 836 Fax: +385 1 3793 345	HR (Zagreb)	participant	5˙217.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Eye cataracts, leading to the loss of vision present a major problem for the aging population. This is currently cured by surgical procedure which requires a viscoelastic High Molecular Weight (HMW) product of Ophthalmic Viscosurgical Device to fill the space in the eye created during the surgery and to protect the healthy endothelial cells. Due to the growing elderly population, this market segment is expected to grow at least 7% per year and will reach €80 Mn in the EU and €240 Mn worldwide by 2014. The market need for (HMW) products is currently served by Hyaluronic acid (HA) and cheaper alternatives derived from cellulose with properties inferior to HA. The manufacturers have currently to rely on few suppliers of the high-quality raw materials i.e. roosters bred on a special diet. The animal nature of the raw materials makes the SMEs particularly vulnerable in light of a bird flu outbreak, creating the threat of losing up to an entire year supply of the raw material with a single outbreak in the region. In addition, using raw materials of animal origin in humans requires compliance with existing EU regulations (EC 1774/2002 and Directive 90/426/EEC, and also Directive 86/609/EEC, 3 R’s Declaration, and REACH). Hence EU SMEs such as ourselves realize that we should switch to a non-animal source of HMW substance, as a substitute to rooster combs originating HA. The main objective of the OkraVision project is to substitute animal based production of HMW HA with a cheaper and non-animal HMW substance: Rhamnopyranose–Galactopyranose–Galactopyranosyluronic Acid (RGGA) from the okra plant (fruit) with the targeted chain length of 800-1000 units, MW of 5-6 MDa, and the targeted zero shear viscosity of 1-3 Mn mPas for 1-2.5% aqueous solution. This will be done by developing a continuous and automised extraction and purification process of HMW RGGA from the okra fruit with a production efficiency of 3 g of RGGA from 1 kg (0.3% weight-to-weight) of sliced okra fruit.'